Amivantamab for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer

The past decade has witnessed a dramatic shift in the treatment approach for patients with metastatic non–small cell lung cancer (mNSCLC), with the identification and understanding of EGFR mutations paving the way for numerous groundbreaking therapies.¹ However, despite these advances, the 5-year overall survival (OS) rate for mNSCLC is still less than 10%.²